A randomized crossover study comparing different tacrolimus formulations to reduce intrapatient variability in tacrolimus exposure in kidney transplant recipients

他克莫司 医学 钙调神经磷酸酶 泌尿科 肾移植 置信区间 CYP3A5 肾移植 内科学 药理学
作者
Kim L. W. Bunthof,Linda Al‐Hassany,Gizal Nakshbandi,Dennis Alexander Hesselink,Ron H. N. van Schaik,Marc A G J ten Dam,Marije C. Baas,Luuk B. Hilbrands,Teun van Gelder
出处
期刊:Clinical and Translational Science [Wiley]
卷期号:15 (4): 930-941 被引量:18
标识
DOI:10.1111/cts.13206
摘要

A high intrapatient variability (IPV) in tacrolimus exposure is a risk factor for poor long-term outcomes after kidney transplantation. The main objective of this trial was to investigate whether tacrolimus IPV decreases after switching patients from immediate-release (IR)-tacrolimus to either extended-release (ER)-tacrolimus or LifeCyclePharma (LCP)-tacrolimus. In this randomized, prospective, open-label, cross-over trial, adult kidney transplant recipients on a stable immunosuppressive regimen, including IR-tacrolimus, were randomized for conversion to ER-tacrolimus or LCP-tacrolimus, and for the order in which IR-tacrolimus and the once-daily formulations were taken. Patients were followed 6 months for each formulation, with monthly tacrolimus predose concentration assessments to calculate the IPV. The IPV was defined as the coefficient of variation (%) of dose corrected predose concentrations. Ninety-two patients were included for analysis of the primary outcome. No significant differences between the IPV of IR-tacrolimus (16.6%) and the combined once-daily formulations (18.3%) were observed (% difference +1.7%, 95% confidence interval [CI] -1.1% to -4.5%, p = 0.24). The IPV of LCP-tacrolimus (20.1%) was not significantly different from the IPV of ER-tacrolimus (16.5%, % difference +3.6%, 95% CI -0.1% to 7.3%, p = 0.06). In conclusion, the IPV did not decrease after switching from IR-tacrolimus to either ER-tacrolimus or LCP-tacrolimus. These results provide no arguments to switch kidney transplant recipients from twice-daily (IR) tacrolimus formulations to once-daily (modified-release) tacrolimus formulations when the aim is to lower the IPV.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
kkkk发布了新的文献求助10
刚刚
1秒前
ce完成签到 ,获得积分10
1秒前
molihuakai的应助被迷路依白采纳,获得10
2秒前
纯真大象完成签到,获得积分10
2秒前
yyds发布了新的文献求助50
3秒前
molihuakai的应助被D调的华丽采纳,获得10
3秒前
华仔的应助被D调的华丽采纳,获得10
3秒前
hzq完成签到,获得积分10
3秒前
CarryLJR的应助被龙澍采纳,获得10
3秒前
科目三的应助被D调的华丽采纳,获得10
3秒前
4秒前
华仔的应助被D调的华丽采纳,获得10
4秒前
脑洞疼的应助被D调的华丽采纳,获得10
4秒前
隐形曼青的应助被D调的华丽采纳,获得10
4秒前
orixero的应助被D调的华丽采纳,获得10
4秒前
4秒前
万能图书馆的应助被D调的华丽采纳,获得10
4秒前
小蘑菇的应助被D调的华丽采纳,获得10
5秒前
星辰大海的应助被砺行采纳,获得100
5秒前
molihuakai的应助被D调的华丽采纳,获得10
5秒前
小马甲的应助被soda采纳,获得10
5秒前
September发布了新的文献求助10
5秒前
5秒前
7秒前
kuku发布了新的文献求助10
10秒前
10秒前
今后的应助被许伟洋采纳,获得10
10秒前
Luo完成签到,获得积分10
10秒前
11秒前
MM发布了新的文献求助10
14秒前
Yaang发布了新的文献求助30
14秒前
迷路依白发布了新的文献求助10
14秒前
15秒前
余溪发布了新的文献求助10
16秒前
桐桐的应助被机灵的友琴采纳,获得10
17秒前
曲妥珠单抗完成签到,获得积分10
17秒前
hdf完成签到,获得积分20
19秒前
SciGPT的应助被111采纳,获得10
20秒前
20秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
Grapes 1000
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8178960
求助须知:如何正确求助?哪些是违规求助? 9569638
关于积分的说明 21805682
捐赠科研通 7774071
什么是DOI,文献DOI怎么找? 3432955
关于科研通互助平台的介绍 2556897
邀请新用户注册赠送积分活动 2478640